Neurocrine (NBIX)

Neurocrine (NBIX) Stock Price & Analysis


NBIX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$89.04 - $126.30
Previous Close$117.12
Average Volume (3M)686.44K
Market Cap
Enterprise Value$10.62B
Total Cash (Recent Filing)$1.10B
Total Debt (Recent Filing)$255.80M
Price to Earnings (P/E)62.7
Feb 06, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.87
Shares Outstanding98,251,923
10 Day Avg. Volume638,774
30 Day Avg. Volume686,439
Standard Deviation0.10
Financial Highlights & Ratios
Price to Book (P/B)5.67
Price to Sales (P/S)7.70
Price to Cash Flow (P/CF)13.20
P/FCF Ratio13.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.95
Enterprise Value/Gross Profit7.24
Enterprise Value/Ebitda39.49
Price Target Upside13.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19



Ownership Overview

24.46% Mutual Funds
51.92% Other Institutional Investors
22.05% Public Companies and
Individual Investors


What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $89.04 and its highest was $126.30 in the past 12 months.
    What is Neurocrine’s market cap?
    Currently, no data Available
    When is Neurocrine’s upcoming earnings report date?
    Neurocrine’s upcoming earnings report date is Feb 06, 2024 which is in 66 days.
      How were Neurocrine’s earnings last quarter?
      Neurocrine released its earnings results on Oct 31, 2023. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.039 by -$0.219.
        Is Neurocrine overvalued?
        According to Wall Street analysts Neurocrine’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Neurocrine pay dividends?
          Neurocrine does not currently pay dividends.
          What is Neurocrine’s EPS estimate?
          Neurocrine’s EPS estimate is $1.22.
            How many shares outstanding does Neurocrine have?
            Neurocrine has 98,251,920 shares outstanding.
              What happened to Neurocrine’s price movement after its last earnings report?
              Neurocrine reported an EPS of $0.82 in its last earnings report, missing expectations of $1.039. Following the earnings report the stock price went up 3.556%.
                Which hedge fund is a major shareholder of Neurocrine?
                Among the largest hedge funds holding Neurocrine’s share is Deerfield Management Company, LP. It holds Neurocrine’s shares valued at 136M.


                  Company Description


                  Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.


                  Top 5 ETFs holding NBIX

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Russell 1000 Growth ETF
                  Vanguard Russell 1000 ETF
                  Vanguard Russell 3000 ETF
                  SPDR S&P 1500 Value Tilt ETF
                  Up to five ETFs with an Outperform Smart Score that hold NBIX. The ETFs are listed according to market value of NBIX within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  ACADIA Pharmaceuticals
                  Ligand Pharma

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis